Leonard S. Schleifer

2020

In 2020, Leonard S. Schleifer earned a total compensation of $135.4M as President and Chief Executive Officer at Regeneron Pharmaceuticals, a 531% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$3,567,714
Salary$1,480,119
Stock Awards$130,000,032
Other$302,256
Total$135,350,121

Schleifer received $130M in stock awards, accounting for 96% of the total pay in 2020.

Schleifer also received $3.6M in non-equity incentive plan, $1.5M in salary and $302.3K in other compensation.

Rankings

In 2020, Leonard S. Schleifer's compensation ranked 12th out of 9,063 executives tracked by ExecPay. In other words, Schleifer earned more than 99.9% of executives.

ClassificationRankingPercentile
All
12
out of 9,063
100th
Division
Manufacturing
1
out of 3,845
100th
Major group
Chemicals And Allied Products
1
out of 1,397
100th
Industry group
Drugs
1
out of 1,184
100th
Industry
Pharmaceutical Preparations
1
out of 890
100th
Source: SEC filing on April 23, 2021.

Schleifer's colleagues

We found four more compensation records of executives who worked with Leonard S. Schleifer at Regeneron Pharmaceuticals in 2020.

2020

George Yancopoulos

Regeneron Pharmaceuticals

Chief Scientific Officer

2020

Andrew Murphy

Regeneron Pharmaceuticals

Executive Vice President, Research

2020

Daniel Van Plew

Regeneron Pharmaceuticals

Executive Vice President and General Manager, Industrial Operations and Product Supply

2020

Robert Landry

Regeneron Pharmaceuticals

Chief Financial Officer

News

You may also like